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Abstract
IgA nephropathy is the most common form of primary glomerulonephritis worldwide. Mucosal infections and food
antigens, including wheat gluten, have been proposed as potential contributing environmental factors. Increased immune
reactivity to gluten and/or association with celiac disease, an autoimmune disorder triggered by ingestion of gluten, have
been reported in IgA nephropathy. However, studies are inconsistent about this association. We aimed to evaluate the
proposed link between IgA nephropathy and celiac disease or immune reactivity to gluten by conducting a comprehensive
analysis of associated serologic markers in cohorts of well-characterized patients and controls. Study participants included
patients with biopsy-proven IgA nephropathy (n = 99), unaffected controls of similar age, gender, and race (n = 96), and
patients with biopsy-proven celiac disease (n = 30). All serum specimens were tested for IgG and IgA antibodies to native
gliadin and deamidated gliadin, as well as IgA antibody to transglutaminase 2 (TG2). Anti-TG2 antibody-positive
nephropathy patients and unaffected controls were subsequently tested for IgA anti-endomysial antibody and genotyped
for celiac disease-associated HLA-DQ2 and -DQ8 alleles. In comparison to unaffected controls, there was not a statistically
significant increase in IgA or IgG antibody reactivity to gliadin in individuals with IgA nephropathy. In addition, the levels of
celiac disease-specific serologic markers, i.e., antibodies to deamidated gliadin and TG2, did not differ between IgA
nephropathy patients and unaffected controls. Results of the additional anti-endomysial antibody testing and HLA
genotyping were corroborative. The data from this case-control study do not reveal any evidence to suggest a significant
role for celiac disease or immune reactivity to gluten in IgA nephropathy.
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Introduction
Immunologic sensitivity to dietary gluten (comprised of gliadin
and glutenin proteins) from wheat and related cereals is most
extensively studied and best understood in the context of celiac
disease and wheat allergy [1]. In celiac disease, the ensuing innate
and adaptive immune responses to ingested gluten lead to
inflammation and villous atrophy in the small intestine, although
the condition is also known to have a number of extra-intestinal
manifestations [2]. Genetic susceptibility in celiac disease is closely
linked to genes for class II human leukocyte antigens (HLA) DQ2
and DQ8 [3]. The associated humoral immune response includes
antibodies to native and deamidated sequences of gliadin, as well
as autoantibodies against endomysial tissue, the primary target of
which is the transglutaminase 2 (TG2) enzyme [4]. IgA anti-TG2
(or anti-endomysial) autoantibody is considered to be the most
specific and sensitive serologic marker of the condition, being used
widely to aid diagnosis [5]. Some individuals, despite lacking the
required serologic, histologic, or genetic markers of celiac disease
and wheat allergy, experience intestinal or extra-intestinal
symptoms in response to ingestion of wheat, sometimes in
conjunction with elevated antibody reactivity to native gliadin
[6]. The term ‘‘non-celiac gluten sensitivity’’ has been proposed to
refer to the spectrum of symptoms reported by these patients [1],
although a role for gluten as the specific culprit has not been well
established [6].
Primary IgA nephropathy (IgAN) is the most common form of
primary glomerulonephritis. IgAN patients present with micro-
scopic or intermittent macroscopic hematuria, varying degrees of
proteinuria, and often develop renal insufficiency [7]. There is no
disease-targeted treatment for IgAN and the factors that lead to
disease development are poorly understood. A hallmark of IgAN
pathogenesis is a dysregulation in the synthesis and metabolism of
IgA that favors formation of IgA-containing immune complexes
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and their subsequent mesangial deposition [7,8]. Although several
recent studies highlight the contribution of genetic factors in the
pathogenesis of IgAN, environmental exposures, including immu-
nogenic molecules of microbial or food origin have also been
suggested to play a role [9]. Ingestion of wheat gluten has been
reported to induce IgA mesangial deposits in BALB/c mice in one
study [10]. There are also case reports indicating positive outcome
or alteration of certain immune abnormalities in response to
gluten restriction in IgAN [11–13]. Of particular note, elevated
immune reactivity to wheat gluten has been reported to be
associated with IgAN in several studies, with rates of 30–50% or
greater positivity for IgA antibodies to gliadin proteins in affected
patients[14–16]. Some studies have also described increased
frequency of markers that have greater specificity for celiac
disease, including anti-endomysial antibodies, or of biopsy-proven
celiac disease, in the context of IgAN [17,18]. Reports from other
investigators have challenged these findings [19–21]. Overall,
these studies have been limited by small sample sizes, lack of
suitable control groups, and/or technical issues regarding assay
methodology, rendering them inconclusive. In the current study,
we evaluated the proposed connection between IgAN and celiac
disease or immune reactivity to gluten through comprehensive
analysis of associated serologic markers in a comparatively large
and well-characterized case-control population.
Methods
Patients and Controls
Study participants included 99 patients with IgAN and 96
unaffected controls of similar age, gender, and race, all of them
residing in New York or New Jersey. All cases carried a biopsy
diagnosis of IgAN, defined by typical light microscopy features and
predominant IgA staining on kidney tissue immunofluorescence in
the absence of liver disease or other autoimmune conditions.
Disease duration, for all patients and regardless of whether they
were eventually transplanted, was calculated as the time from
initial diagnosis made on native kidney biopsy. Screening
questionnaires were used to evaluate the general health of
unaffected controls. Individuals who reported having a history of
renal disease, proteinuria, or hematuria were excluded. Fifty-four
(56%) of the unaffected controls were also screened by urinalysis
and were negative for hematuria or proteinuria. Additional
controls included 30 patients with biopsy-proven celiac disease,
diagnosed according to previously described criteria [2]. Written
informed consent was obtained for all study participants. This
study was approved by the Institutional Review Board of
Columbia University Medical Center. Serum and DNA samples
were kept at 280uC to maintain stability.
Gliadin
The antigen used for the anti-gliadin antibody assays was the
Prolamine Working Group (PWG) reference gliadin, which was
extracted from a combination of 28 different wheat varieties, as
previously described [22]. The protein profile of the PWG gliadin
extract was assessed by SDS-polyacrylamide gel electrophoresis,
using 10% NuPAGE Bis-Tris precast gels and 3-(N-morpholino)-
propanesulfonic acid (MOPS) buffer (Life Technologies, Carlsbad,
Calif.).
Anti-gliadin Antibodies
Serum IgA and IgG antibodies to gliadin were measured by
enzyme-linked immunosorbent assay (ELISA) as previously
described [23,24], with minor modifications. A 2 mg/mL stock
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Maxisorp round-bottom polystyrene plates (Nunc, Roskilde,
Denmark) were coated with 50 mL/well of a 0.01 mg/mL solution
of gliadin in 0.1 M carbonate buffer (pH 9.6) or were left uncoated
to serve as control wells. After incubation at 37uC for 1 h, all wells
were washed and blocked by incubation with 1% bovine serum
albumin (BSA) in phosphate buffered saline containing 0.05%
Tween-20 (PBST) for 1.5 h at room temperature. Serum samples
were diluted at 1:800 for IgG measurement and at 1:200 for IgA
measurement, added at 50 mL/well in duplicates, and incubated
for 1 h. Each plate contained a positive control sample from a
patient with biopsy-proven celiac disease and elevated IgG and
IgA antibodies to gliadin. After washing the wells, they were
incubated with HRP-conjugated anti-human IgG (GE Healthcare,
Piscataway, N.J.) or IgA (MP Biomedicals, Santa Ana, Calif.)
secondary antibodies for 50 min. The plates were washed and
50 mL of developing solution, comprising of 27 mM citric acid,
50 mM Na2HPO4, 5.5 mM o-phenylenediamine, and 0.01%
H2O2 (pH 5), was added to each well. After incubating the plates
at room temperature for 20 min, absorbance was measured at
450 nm. Absorbance values were corrected for non-specific
binding by subtraction of the mean absorbance of the associated
BSA-coated control wells. The corrected values were first
normalized according to the mean value of the positive control
duplicate on each plate. The mean antibody level for the healthy
control cohort was then set as 1.0 AU and all other results were
normalized to this value.
Anti-deamidated Gliadin Antibodies
IgA and IgG antibody reactivities to a previously described
glutamine-glutamate substituted trimer of a fusion peptide,
containing the sequences PLQPEQPFP and PEQLPQFEE [25],
were measured by separate ELISAs, according to the manufac-
turer’s protocols (Euroimmun AG, Lubeck, Germany).
Anti-transglutaminase 2 (TG2) Antibody
IgA antibody to recombinant human TG2 was measured by
ELISA, according to the manufacturer’s protocol (Euroimmun
AG).
Anti-endomysial Antibody
Sera from anti-TG2 antibody-positive subjects were tested in
duplicate for anti-endomysial antibody reactivity by an indirect
immunofluorescence assay, using the NOVA Lite Monkey
Esophagus IFA Kit/Slides (Inova, San Diego, Calif.), according
to the manufacturer’s instructions.
HLA Genotyping
High resolution HLA-DQA1 and -DQB1 genotyping of anti-
TG2 antibody-positive subjects was performed by DNA amplifi-
cation through multiplex polymerase chain reaction (PCR),
followed by detection with sequence-specific oligonucleotide
(SSO) probes [26]. Extracted DNA was amplified and hybridized
to a suspension of fluorescent beads containing immobilized DNA
probes specific to DQA1 and DQB1 polymorphic sequences,
according to the kit manufacturer’s instructions (One Lambda,
Canoga Park, Calif.). The hybridized beads were analyzed on a
LABScan 100 platform, utilizing Luminex technology, and
interpreted using software provided by the manufacturer (One
Lambda). Presence or absence of celiac disease-associated
DQA1*0501/0505-DQB1*0201/0202 (DQ2) and DQA1*03-
DQB1*0302 (DQ8) genes was determined.
Data Analysis
Differences between groups were analyzed by the one-way
analysis of variance (ANOVA) with post-hoc testing for multiple
comparisons (continuous data), and by the Fisher’s exact test
(nominal data). Adjustment for covariate effect (age, gender, and
race) was carried out by analysis of covariance (ANCOVA), using
the general linear model. Elevated levels of anti-gliadin antibody
were defined as values at the 95th percentile or higher in the
healthy control group. For IgA anti-TG2 antibody and IgA/IgG
anti-deamidated gliadin antibodies, cutoffs for positivity were
assigned by the manufacturer (1.0 AU). Differences with p values
of ,0.05 were considered to be statistically significant. Statistical
analyses were performed with Prism 6 (GraphPad, San Diego,
Calif.) and Minitab 16 (Minitab, State College, Pa.).
Figure 1. Gel electrophoresis profile of the gliadin preparation
used for the anti-gliadin antibody assays. A) 5 mg of protein
loaded; B) 10 mg of protein loaded.
doi:10.1371/journal.pone.0094677.g001
Figure 2. Mean levels of A) IgA and B) IgG antibody to gliadin
in IgAN patients and unaffected controls, as well as individuals
with celiac disease. Error bars represent the standard error of the
mean. * = p,0.05, *** = p,0.001.
doi:10.1371/journal.pone.0094677.g002
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Results
Patients and Controls
The demographic and clinical characteristics of the patients and
controls are shown in Table 1. There was no significant difference
between the two groups with regard to age, gender, or race.
Among the IgAN patients, 49% were receiving immunosuppres-
sants at the time of sampling, including 30 on mycophenolate
(alone or in combination with other agents), 14 on glucocorticoid
monotherapy, and 2 on combination cyclophosphamide/gluco-
corticoid. In addition, 79 (80%) were being treated with
angiotensin-converting enzyme inhibitor (ACEI), angiotensin
receptor blocker (ARB), or both.
Gliadin
The gel electrophoresis profile of the PWG gliadin used for the
anti-gliadin antibody assays indicated the presence of all main
types of gliadin proteins, a/b, c, and v. The mixture also
contained high and low molecular weight glutenin subunits (Fig. 1).
Antibody Measurements and HLA Genotyping
Mean levels of IgA and IgG class antibodies to gliadin and
deamidated gliadin, as well as IgA antibody to TG2, for patient
and control groups are presented in Fig. 2 and Fig. 3. The IgAN
patient cohort exhibited slightly higher mean IgA antibody
reactivity to gliadin when compared with the unaffected control
group, but the difference was not statistically significant (p=0.11)
(Fig. 2). IgAN patients had lower levels of IgG antibody to gliadin
in comparison to unaffected controls and the difference remained
significant after adjusting for the covariates of age, gender, and
race (p,0.05) (Fig. 2). There were no differences in levels of IgA
antibody to TG2 (p=0.60), IgA antibody to deamidated gliadin
(p=0.45), or IgG antibody to deamidated gliadin (p=0.99)
between IgAN patients and unaffected controls. Patients with
celiac disease exhibited significantly greater levels of IgA and IgG
antibodies to gliadin and deamidated gliadin, as well as IgA
antibody to TG2, when compared to IgAN patients or unaffected
controls (p,0.001 for all comparisons).
There were no significant differences in the frequencies of any
of the examined serologic markers between the IgAN cohort and
the unaffected control group. Specifically, 8/99 (8%) of IgAN
patients and 4/96 (4%) of unaffected controls were positive for IgA
anti-gliadin antibody (p=0.4), whereas 1/99 (1%) of IgAN patients
and 4/96 (4%) of unaffected controls were positive for IgG anti-
gliadin antibody (p=0.2). Three (3%) IgAN patients and 3 (3%)
unaffected controls were positive for IgA anti-TG2 antibody
Figure 3. Mean levels of A) IgA anti-human TG2, B) IgA anti-deamidated gliadin, and C) IgG anti-deamidated gliadin in IgAN
patients and unaffected controls, as well as individuals with celiac disease. Error bars represent the standard error of the mean. *** = p,
0.001.
doi:10.1371/journal.pone.0094677.g003
Table 2. Antibody and HLA data for the anti-TG2 antibody-positive patients and controls.
Subjects Anti-TG2 antibody level (AU)1 Anti-endomysial antibody reactivity2 HLA3
IgAN patient 1 1.25 Negative DQ2
IgAN patient 2 6.17 Positive DQ8










1Measured by ELISA (cutoff = 1.0).
2Detected by indirect immunofluorescence assay.
3DQ2=DQA1*0501/0505-DQB1*0201/0202; DQ8=DQA1*03-DQB1*0302.
doi:10.1371/journal.pone.0094677.t002
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(p=0.9). Of these, 1 IgAN patient and 1 control had values that
were near the cutoff and therefore equivocal. Eight (8%) IgAN
patients and 4 (4%) unaffected controls were positive for IgA anti-
deamidated gliadin antibody (p=0.4), while 1 (1%) IgAN patients
and 4 (4%) unaffected controls were positive for IgG anti-
deamidated gliadin antibody (p=0.2).
In order to further assess the likelihood of celiac disease in the 3
IgAN patients and 3 unaffected controls who were anti-TG2
antibody-positive, genotyping for celiac disease-associated HLA-
DQ2/DQ8 alleles and testing for IgA anti-endomysial antibody
reactivity were performed. Three of 3 IgAN patients and 2 of 3
unaffected controls were HLA DQ2- or DQ8-positive, while 1
unaffected control was positive for one half of the DQ2
heterodimer (Table 2). These genotypes are all consistent with
celiac disease. Two of 3 IgAN patients and 2 of 3 controls were
positive for anti-endomysial antibody, corresponding to the same
individuals that were unequivocally positive for anti-TG2 antibody
(Table 2). These 2 patients and 2 unaffected controls are likely to
have celiac disease.
A significant correlation between antibody levels and duration
of disease was not found in the IgAN patient cohort. There was no
significant difference for any of the antibody markers based on
treatment status.
Discussion
The data from this study indicate that, compared with
unaffected controls, neither antibodies to native gliadin, nor the
more specific and sensitive markers of celiac disease, i.e.,
antibodies to TG2 and deamidated gliadin, are significantly
elevated in patients with IgAN. Furthermore, the observed
incidence of unequivocal positivity for anti-TG2 and anti-
endomysial antibodies points to a frequency of celiac disease in
the IgAN and unaffected control groups that is similar to that
reported for the general population [27–29]. The concomitant
existence of slightly increased IgA and decreased IgG reactivity to
gluten in the IgAN cohort compared with unaffected controls is
likely to be related to the systemic IgA-restricted B cell
hyperactivity. Earlier studies on B cells from IgAN patients have
shown that the antibody response to antigenic stimulation is
primarily geared towards IgA synthesis, with an apparent decline
in IgG release [30,31].
A recently published large epidemiological study from Sweden
investigated whether IgAN occurs more commonly in patients
with celiac disease than in reference individuals [32]. Despite the
remarkably large sample size for each group, the study found an
increase in the rate of IgAN among patients with celiac disease
compared with reference individuals that was marginally signifi-
cant, possibly attributable to the inherent bias towards further
evaluation and follow-up of individuals already diagnosed with a
chronic disease. The Swedish study also demonstrated a low
absolute risk of developing IgAN, with only 0.026% of celiac
disease patients being diagnosed later with the condition. While
the two studies are different in objective and methodology, the
Swedish epidemiologic data and the serologic analysis by our
group are confirmatory in that they show the co-occurrence of
celiac disease and IgAN to be a rare event.
Although the current study is the largest and most comprehen-
sive analysis of serologic markers of celiac disease and immune
reactivity to gluten in IgAN to date, it does have some limitations.
First, it is a single-center study, based primarily on individuals
identified in their records as being white and residing in the
northeastern United States. Thus our findings may not be
generalizable to other races or geographic locations. In addition,
we could not control for the diet of the research participants,
which may contribute to levels of antibodies against gliadin and
other antigens in patients and controls. Finally, duodenal biopsy,
which is regarded as the gold standard for diagnosis of celiac
disease, was not part of this study. However, considering the
excellent sensitivity and specificity of anti-TG2 (and to a somewhat
lesser extent anti-deamidated gliadin) antibodies [5], it can be
concluded with high certainty that the patients with normal
serology do not have celiac disease.
In conclusion, the data from this study do not provide any
evidence to suggest frequent co-occurance of IgAN with celiac
disease or with increased immune reactivity to gluten. It should be
noted that the results do not address whether immune reactivity to
gluten can ever be a contributing factor for IgAN. However, the
study’s sample size is large enough to effectively rule out the
suggested high rates of elevated antibody to gluten among IgAN
patients. Celiac disease and immune reactivity to gluten are not
likely to be significant players in the pathophysiology of IgAN.
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